Context: Bile acids (BAs) are signaling molecules controlling energy homeostasis that can be both toxic and protective for the liver. BA alterations have been reported in obesity, insulin resistance (IR), and nonalcoholic steatohepatitis (NASH). However, whether BA alterations contribute to NASH independently of the metabolic status is unclear.
B
ile acids (BAs) are amphipathic molecules that facilitate absorption of dietary fat and lipophilic vitamins in the small intestine. However, owing to their detergent properties, BAs also are potentially harmful when accumulating, as seen in cholestatic liver diseases. BA overload induces hepatotoxicity by activation of inflammatory, oxidative stress, and necrotic cell death pathways (1, 2) . Therefore, BA pool size and metabolism are under tight negative retrocontrol via activation of nuclear receptors, such as the farnesoid X (FXR), pregnane X (PXR), and vitamin D (VDR) receptors. BAs also activate cell surface receptors, such as the G protein-coupled BA receptor-1 [GPBAR1/Takeda G protein-coupled receptor 5 (TGR5)] and sphingosine-1-phosphate receptor 2 (3) .
Chenodeoxycholic acid (CDCA) and cholic acid (CA) are the major primary BAs synthesized from cholesterol in the liver (4) . Before secretion into bile, BAs are conjugated (mainly to glycine, less to taurine in humans), decreasing their hydrophobicity. Primary BAs are converted in the intestine into more hydrophobic secondary BAs, deoxycholic acid (DCA) and small amounts of lithocholic acid, hyodeoxycholic acid, and ursodeoxycholic acid (UDCA). Most BAs are reabsorbed in the distal intestine and transported back to the liver via the portal circulation. A small proportion of BA escapes this enterohepatic cycle and reaches peripheral organs via the systemic circulation.
BAs also act as signaling molecules controlling glucose, lipid, and energy homeostasis, notably via activating FXR and TGR5 (3) . In humans, interruption of enterohepatic BA circulation using BA sequestrants improves both lipid and glucose metabolism through mechanisms involving increased L-cell glucagon-like peptide-1 (GLP-1) production and enhancement of splanchnic glucose utilization (5, 6) .
Nonalcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease and strongly associates with obesity and insulin resistance (IR). NAFLD encompasses a spectrum ranging from isolated steatosis to nonalcoholic steatohepatitis (NASH), characterized by steatosis, necroinflammatory changes (ballooned hepatocytes and lobular inflammation), and varying degrees of liver fibrosis (7) . IR is a common feature in individuals with NAFLD and, reciprocally, .70% of type 2 diabetic (T2D) patients have fatty liver and rapidly progress to NASH (8) . NASH pathogenesis is still unclear and appears multifactorial, resulting from several deleterious events occurring in parallel and involving the interaction of multiple organs, with the gut/liver axis playing a crucial role (9) . There is also a genetic basis in NASH and, interestingly, the phospholipase domain-containing protein 3 (PNPLA3) I148M polymorphism associates with the severity of necroinflammatory changes independently of metabolic factors (10).
Obesity, T2D, and NAFLD are associated with dysbiosis (11) . The intestinal microbiota modulates the development of metabolic diseases in part through BAs, because the microbiota deconjugates and converts primary into secondary BAs. Whereas it is unclear whether systemic total BA concentrations are altered in obesity (12, 13) , they are elevated in T2D patients (3, 14) . Moreover, the peripheral blood BA pool composition is altered in IR due to impaired insulin-mediated 12a-hydroxylase (CYP8B1) downregulation, resulting in increased 12a-hydroxylated BA (CA, DCA, and their conjugated forms) (15) . Bariatric surgery, especially Roux-en-Y gastric bypass, which not only reduces body weight but also reverses T2D and NAFLD, increases peripheral blood BA levels, and BA changes might be involved in NAFLD reversion after bariatric surgery (3, 16) .
However, whether alterations in BA metabolism play a role in the pathogenesis of NASH is unclear. Recent publications reported increased hepatic BA concentrations accompanied with altered synthesis in NASH patients (17, 18) , suggesting the existence of a mild cholestatic injury in NASH. However, liver tissue BA composition and concentration analysis does not allow discrimination of intracellular, ductular, or blood origins. Changes in BA profile in plasma and feces were also described, notably increased total and primary BAs in NASH patients (19) (20) (21) (22) (23) . However, these studies compared NASH patients to controls with lower body weight, fasting plasma glucose (FPG) (19) , and/or IR (20) (21) (22) (23) . Because body mass index (BMI) and the insulin sensitivity status of the patients were not accounted for in these studies, it is unclear whether NASH and its histological components per se are associated with alterations in BA metabolism.
Therefore, we investigated BA metabolism in a cohort of drug-naive obese patients extensively phenotyped for metabolic parameters and biopsy-proven NASH. Plasma BA profiling coupled with transcriptomic analysis of BA metabolism and signaling in liver biopsies were compared between NASH patients and BMI-and IR-matched control (no-NASH) patients. (24) . Patients were prospectively screened for the presence of NAFLD, and when NAFLD was suspected from abnormal blood biochemistry assays [alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT), g-glutamyl transpeptidase (GGT)] or ultrasound features, a liver biopsy was subsequently proposed. Exclusion criteria were alcohol consumption, previous bariatric surgery, liver diseases other than NAFLD, diagnosed T2D (as diabetic patients constitute another specific risk group for NAFLD, and as long-term diabetes and its treatments potentially influence the presence and severity of NAFLD, this was considered a potential confounder and therefore excluded; patients who were de novo diagnosed with T2D as a result of their work-up were, however, included in the study), and antidiabetic, lipid-lowering, or antibiotic treatments. The study protocol is part of the HEPADIP protocol (Belgian registration number B30020071389); it was approved by the Ethical Committee of the Antwerp University Hospital (file 6/25/125), and required written informed consent of the patient.
Materials and Methods

Description of the patients
Clinical assessment and biological measurements
Fasting blood was collected in the morning. Plasma glucose, insulin, triglyceride, total, high-density lipoprotein (HDL-C), and low-density lipoprotein (LDL-C) cholesterol concentrations and liver enzymes (ALAT, ASAT, GGT, alkaline phosphatase) were measured as described (10) . IR was estimated using homeostasis model assessment (HOMA-IR) calculated as [insulin (mU/L) 3 glucose (mmol/L)]/22.5.
Histological assessment of liver biopsies
Hematoxylin and eosin, Sirius red, reticulin stain, and Perls' iron stains were routinely performed on all liver biopsies and analyzed by two experienced pathologists blinded to clinical data. The histological features of NAFLD (steatosis, ballooning, lobular inflammation, and fibrosis) were assessed using the NASH Clinical Research Network Scoring System (25) . NASH diagnosis was defined according to recent guidelines requiring the combined presence of steatosis, ballooning, and lobular inflammation (26, 27) . The NAFLD activity score was also calculated. In line with recent insights on the differential role of steatosis and activity of disease, an activity index (AI) was also calculated as the sum of ballooning (range, 0 to 2) and lobular inflammation (range, 0 to 3), hence ranging from 0 to 5 (25, 28) .
Selection and matching of patients for BA metabolism analysis
Among the whole cohort, 152 patients had liver biopsies, and a complete clinical and biological dataset is available for further analyses. For the present study, patients with cholecystectomy or cholelithiasis were excluded. Furthermore, to dissect influences of NASH and metabolic features, two clearly distinct histological phenotypes were selected for comparison and matched on BMI and HOMA-IR. Selection of the NASH patients was hence based on the unequivocal presence of NASH. For the no-NASH group, patients with normal liver or minor lesions largely insufficient for the diagnosis of NASH, as well as absence of fibrosis, were selected. Cases with borderline lesions (n = 4) were not included in the present study. Then, NASH patients were matched with no-NASH patients on quartiles of BMI (Q1 , 35.6, Q2 , 39.5, Q3 , 43.2, Q4 $ 43.2 kg/m 2 ) and HOMA-IR (Q1 , 2.38, Q2 , 3.49, Q3 , 4.89, Q4 $ 4.89). Patients that could not be matched were excluded. This resulted in 32 NASH and 26 no-NASH patients, representative of the whole cohort (Supplemental Table 1 ).
Transcriptomic analysis of liver biopsies
Total RNA was prepared and transcriptomic analysis with Affymetrix GeneChip arrays (HuGene 2.0 ST) was performed as described (24, 29) . Signals were normalized by the Robust Multiarray Average method, and the baseline was adjusted to the median of all samples. Proprietary.CEL files were imported into Partek Genomics Suite 6.6 for analyses. Using the linear models for microarray data, 31,135 transcripts were tested for differential expression between NASH (n = 32) and no-NASH (n = 26) patients. Pathway analysis, including KEGG pathway and gene ontology term enrichment, was performed on transcripts coding for proteins that exhibit a significant .20% differential expression level between NASH and no-NASH patients.
Subsequently, all genes involved in BA metabolism were further analyzed based on the KEGG BA synthesis and bile secretion pathways (www.kegg.jp) and literature (4, 18, 30) , resulting in 87 genes. A heat map was generated using the heatmap.2 function in the gplots package (R project) including these 87 genes. Hierarchical clustering was performed to group patients by Euclidean distance. Clustering was not performed on genes.
Plasma measurements of BA, 7a-hydroxy-4-cholesten-3-one, and fibroblast growth factor 19
All measurements were performed on fasting EDTA plasma collected in the morning. Twenty-one BA species were quantified by liquid chromatography-tandem mass spectrometry as previously described (31) . BA concentrations are presented in Supplemental Table 2 , except for UDCA and its conjugated forms that were only detected as trace amounts in these samples.
Plasma 7a-hydroxy-4-cholesten-3-one (C4) was determined as described (32) . Briefly, 100 mL of plasma sample was mixed with 500 mL of purified water, 50 mL of the 0.06 mM D7-C4 internal standard solution, and 60 mL of 1 M hydrochloric acid. Solid-phase extraction was performed using solid phase extraction cartridges (Bound Elut-C18, 200 mg) preconditioned with 2 mL of methanol followed by 2 mL of purified water, upon which the sample was loaded and allowed to pass through it by gravity. The cartridge was washed, the analyte was eluted with MeOH, and the eluted solution was evaporated. The residue was dissolved in 80 mL of methanol and mixed with 10 mL of ammonium acetate buffer (10 mM, pH 6.5), upon which the sample was centrifuged at 13,400 3 g and 10°C for 10 minutes. The supernatant was evaporated. The pellet was then dissolved in 100 mL of MeOH/water (volumeto-volume ratio) and 2 mL was injected into the liquid chromatography-tandem mass spectrometry system (31) . The separation of C4 was carried out on a Kinetex Core-Shell C18 column (100 3 2.1 mm, 5 mm) from Phenomenex. The oven temperature was 30°C. Solvent A was water containing 0.1% formic acid, and solvent B was acetonitrile. Solvents were delivered at a total flow rate of 500 mL/min. After a 2-minute plateau with 75% solvent B, the gradient profile was from 75% solvent B to 95% solvent B linearly in 5 minutes, followed by a 2-minute plateau with 95% solvent B. The column was reequilibrated for 3 minutes. The injection cycle was 12 minutes. Mass spectrometry analysis was carried out in positive ionization mode. The ion source parameters were set as follows: ion spray voltage, 5500 V; nebulizer gas (air) and curtain gas (nitrogen) flows, 50 and 20 psi, respectively; source temperature, 650°C with auxiliary gas flow (air), 50 psi; declustering potential, 100 V; collision cell exit potential, 15 V; collision energy, 31 V. The mass spectrometer was operated at a unit resolution for both Q1 and Q3 with a dwell time of 100 ms in each transition. The methods allow the quantification of C4 within the range of 1 to 200 nM, with interday and intraday precisions , 15%. All of the analytical methods were validated using the Société Française des Sciences et Techniques Pharmaceutiques guidelines.
Plasma fibroblast growth factor 19 (FGF19) concentrations were measured using a human FGF19 Quantikine enzymelinked immunosorbent assay kit DF1900 (R&D Systems).
Statistical analyses
Statistical analyses were performed using the SAS statistical software, version 9.4 (SAS Institute, Cary, NC). Intergroup comparisons of quantitative variables were performed using the general linear model. To obtain normal data distributions, log transformation of some variables was applied in all samples, as indicated in the table legends. For plasma BA, C4, and FGF19 analyses, nonparametric tests were performed. P values for the comparison of distribution (sex, histological grades) between subject groups were assessed using the x 2 test or Fisher's exact test, as indicated in the table legends. Multivariable analyses were performed to compare hepatic gene expression between groups, adjusted on confounding factors, including sex and the PNPLA3 I148M (rs738409) genotype (10) . Statistical significance was considered when P , 0.05.
Results
Characteristics of the studied patients
To analyze BA alterations specifically associated with NASH, independent of obesity or IR, patients with wellestablished NASH and patients with no-NASH were matched on BMI and HOMA-IR, resulting in 32 NASH and 26 no-NASH patients (Supplemental Table 1 ; Table 1 ). The no-NASH patients had a liver with little or no steatosis and hepatic injury (Fig. 1) . In contrast, besides steatosis, NASH patients presented clear signs of disease activity with inflammatory infiltrates (mostly grades 1 and 2) and prominent ballooning (grade 2 in 50% of patients). Approximately 50% of NASH patients presented some degree of fibrosis up to F3 (Supplemental Table 1 ).
Overall, all 58 subjects were severely obese (BMI of 39.8 6 5.8 kg/m 2 ) and presented several features of the metabolic syndrome, that is, mild hypertriglyceridemia (157 6 73 mg/dL) and relatively low plasma HDL-C levels (47 6 13 mg/dL). FPG (84 6 10 mg/dL) was in the normal range, whereas 2-hour postoral glucose levels were slightly elevated (145 6 35 mg/dL), indicative of impaired glucose homeostasis. As could be expected because of the matching on BMI and HOMA-IR, NASH and no-NASH patients displayed no significant difference in terms of metabolic parameters, except a lower plasma HDL-C level in NASH patients (Table 1) .
Systemic BA profile is unchanged in NASH patients First, correlations between each hepatic histological feature and each plasma BA species concentration were analyzed in the 58 studied patients. No correlation, except glycocholic acid with steatosis (r = 0.29, P = 0.03), was found ( Fig. 2A) . Furthermore, comparison of plasma BA species concentrations between NASH and no-NASH patients did not show any significant difference (Fig. 2B) . Total, primary, secondary, free, or conjugated BAs were unchanged with NASH (Supplemental Table 2 ). BA profile composition was also similar between NASH and no-NASH patients (Fig. 2C) . In multivariable analyses, Hepatic gene expression analysis reveals limited BA metabolism and signaling changes in NASH Because previous reports described altered hepatic expression of genes involved in BA synthesis and transport in NASH patients (18, 19) , gene expression profiles were compared by microarray analyses performed on liver biopsies of all NASH and no-NASH patients. Differential expression analysis revealed 713 transcripts dysregulated in NASH. Pathway enrichment analysis showed clear activation of inflammatory response in NASH patients (Supplemental Fig. 1 ). However, no BA pathways (defined by KEGG or gene ontology term) were enriched in NASH.
To analyze in more detail whether changes in hepatic BA metabolism genes may exist, a literature search of all genes involved in BA metabolism (synthesis, transport, conjugation/detoxification, bile secretion, regulation of BA metabolism, and BA-activated signaling pathways) resulted in the identification of 87 genes (Fig. 3) . Unsupervised hierarchical clustering showed that NASH status was not strongly associated with changes in expression of these genes (Fig. 3A) . Only a few BA metabolism genes were significantly dysregulated in NASH (Fig. 3B ): among them, as reported (24) , PPARA was lower, along with CYP3A4 and ABCB11 (also known as BSEP), whereas CYP7A1 and ATP8B1 were higher in NASH patients. Most of these changes were observed when stratifying the patients on steatosis grade (Fig. 3C) , but not when stratified on an AI, except for PPARA (Fig. 3D) .
Because the rate-limiting enzyme of BA synthesis, 7a-hydroxylase (CYP7A1), messenger RNA levels were increased, we measured plasma C4 concentrations, a surrogate marker of hepatic BA synthesis (33) . C4 concentrations did not differ between NASH and no-NASH patients (Fig. 3E) , indicating that the increased CYP7A1 gene expression did not translate into increased BA synthesis.
As it has been suggested that hydrophobic BA (CDCA, DCA) could accumulate in the liver of NASH patients and participate in liver injury (17, 34, 35) , indirect markers of hepatic BA accumulation and injury were examined. Liver enzymes and metabolites known to increase with cholestatic injury were not elevated in NASH patients (Table 1) . Moreover, upon intrahepatic BA overload, the BA receptors FXR, PXR, and VDR initiate protective mechanisms to downregulate BA uptake and synthesis and upregulate BA detoxification and systemic efflux (4) . In this study, hepatic expression of well-known target genes of FXR, PXR, and VDR revealed increased CYP7A1 in NASH (Supplemental Fig. 2 ) whereas its expression is typically repressed by these BA receptors (4). Also, CYP3A4, which is induced upon PXR or VDR activation, and the FXR target gene ABCB11 (BSEP) (4) were downregulated in NASH vs no-NASH patients (Supplemental Fig. 2) . Expression of the membrane BA receptor GPBAR1 (TGR5), which mediates anti-inflammatory responses upon BA activation in Kupffer cells (36) , was also unchanged (not shown). Taken together, these results indicate the absence of major changes in hepatic BA metabolism and intrahepatic BA accumulation in NASH patients compared with BMI-and HOMA-IR-matched controls.
Intestinal BA metabolism is unchanged in NASH patients
Because alterations in fecal BA content associated with dysbiosis were reported in NAFLD patients (23), we also investigated parameters of intestinal BA metabolism and signaling. Because neither intestinal gene expression nor BA profiles could be measured, plasma levels of FGF19, a marker of intestinal FXR activation (37), were measured. No difference was found between patients with and without NASH (62.0 6 53.5 vs 54.7 6 41.1 pg/mL, P = 0.37). Moreover, the ratios of free/conjugated BAs (1.11 6 0.96 vs 1.27 6 1.14, P = 0.56) and secondary/primary BAs (0.80 6 0.48 vs 0.80 6 0.78, P = 0.99), markers of microbiota deconjugation and conversion activities, respectively, were also unchanged in NASH patients.
BA alterations are associated with glucose homeostasis independently of NASH Considering the lack of association between BA alterations and NASH, we finally assessed whether differences in metabolic status correlate with BA metabolism considering the whole (NASH and no-NASH) studied population. Therefore, metabolic parameters were correlated with each plasma BA species concentration (Fig. 4A) . BMI positively correlated with plasma CA (r = 0.36, P = 0.006) and CDCA (r = 0.31, P = 0.02). CA and CDCA also strongly correlated with fasting plasma insulin (CA, r = 0.42, P = 0.0009; CDCA, r = 0.39, P = 0.003) and HOMA-IR (CA, r = 0.45, P = 0.0004; CDCA, r = 0.42, P = 0.001). Additionally, plasma hyocholic acid correlated with FPG (r = 0.39, P = 0.003). In accordance with Haeusler et al. (15) , 12a-hydroxylated BAs (CA, DCA, and their conjugated forms) tended to correlate with fasting plasma insulin (r = 0.14, P = 0.08).
Given the strong correlations between parameters of glucose homeostasis and plasma BA, the 58 subjects were stratified according to IR, and highest vs lowest quartiles of HOMA-IR were compared (for clinical and liver histology parameters, see Supplemental Table 3 ). Unlike in NASH, several changes in systemic BA profile occurred with IR, with notably increased primary (free) BA concentrations ( Fig. 4B and 4C) . Also, the total plasma BA concentration tended to increase in IR patients, which was not the case in NASH patients (Supplemental Table 2 ). Overall, these results show that BA metabolism is correlated with metabolic conditions, especially IR, but not with hepatic lesions.
Discussion
BA metabolism is altered in metabolic disorders associated with NAFLD (3). Because BA overload causes hepatotoxicity in some chronic liver diseases (cholestasis), it is tempting to speculate that BA alterations could participate in NASH pathogenesis, both through their impact on metabolic control and their physicochemical properties potentially causing liver injury. We therefore designed a study to assess BA changes in NASH, independently of confounding metabolic parameters. To our knowledge, this is the first study comparing BA metabolism and associated signaling pathways between patients with and without NASH matched on BMI and IR levels. Another advantage of this cohort is the absence of antidiabetic or lipid-lowering medications, which can interfere with BA metabolism (38) . Our results revealed that neither circulating BA species nor hepatic or intestinal BA metabolism/signaling was altered in NASH. The absence of BA alterations in relationship to NASH suggests that alterations in BA metabolism do not participate in NAFL progression to NASH.
Increased plasma total BA has been reported in NASH patients (19, 21) as well as in IR or T2D patients (14, 39) . Notably, plasma primary BA increased in NASH patients (20) (21) (22) as well as in T2D patients (15, 39) . These BA changes could be attributed to increased hepatic BA synthesis in NASH (23) and T2D (40) patients. Importantly, in all of these studies (19) (20) (21) (22) (23) , NASH patients had higher IR than did controls, suggesting that these BA changes could be confounded by the metabolic status. In the present study, although glucose homeostasis was merely assessed by HOMA-IR, we also found that plasma primary BAs increase with IR (but not with NASH). Given the number of patients and variability of measurements, our study was at least as statistically powerful as the previous reports. Therefore, our study design, comparing NASH patients to BMI-and HOMA-IR-matched controls, suggests that previous results showing increased primary and total BAs are due to IR and not NASH (19) (20) (21) (22) (23) . Our results also indicate that hepatic BA synthesis is not increased in NASH, which is in accordance with the study of Min et al. (41) showing cholesterol accumulation in NASH livers without upregulation of its catabolism.
In our study, we did not find any sign of cholestatic injury or activation of BA receptors. In line, UDCA, which is widely used for the treatment of cholestatic liver diseases, and its tauro-conjugated form failed to show beneficial effects on NASH (42, 43) . This suggests that the mechanisms leading to liver injury and inflammation are different between cholestatic liver diseases and NASH. UDCA, which does not activate FXR, is a hydrophilic BA protecting cellular membranes and preventing cytolysis, endoplasmic reticulum stress, and apoptosis. UDCA also decreases BA uptake and synthesis, stimulates basolateral export pumps, and improves renal excretion (44) . Taken together, this suggests that cholestatic injury is not involved in NASH pathogenesis and that the UDCA's mechanisms of protection are inefficacious in NASH.
BA sequestrants are used to treat cholestatic pruritus as well as hypercholesterolemia and T2D. They prevent intestinal BA absorption, interrupt the enterohepatic cycle, and result in enhanced hepatic cholesterol conversion to BA to maintain the BA pool. Colesevelam treatment decreases LDL-C and reduces FPG and hemoglobin-A1c in T2D patients (5) . However, colesevelam did not improve NASH and even slightly worsened steatosis (45) , again suggesting that interfering with BA metabolism per se is not an efficient therapeutic option for NASH. Interestingly, the FXR agonist obeticholic acid (OCA) is currently in phase 3 clinical development in NASH patients. Phase 2b trial results showed that OCA improves all hepatic histological features, including fibrosis, in NASH patients (46) . OCA reduces hepatic inflammation and fibrosis via inhibition of Kupffer cell and hepatic stellate cell activation in experimental models (47) . Intriguingly, OCA exerts beneficial hepatoprotective effects despite unfavorable metabolic effects, that is, worsening plasma lipid profile (increased LDL-C, decreased HDL-C) and IR (46) . In the liver, FXR is found in two distinct genomic transcriptional regulatory modules, one involved in cellular maintenance and hepatoprotection, and the other in liver-specific metabolic functions, especially glucose, lipid, and BA metabolism (48) . Therefore, it is tempting to speculate that the histological improvement of fibrosing NASH by FXR activation is mediated through the former module of metabolism-independent effects rather than through changes in BA metabolism. Finally, recent studies showed that intestinal FXR activation promotes NAFLD and that its antagonism improves metabolic control and NAFLD in mouse models of obesity (49, 50) . However, intestinal FXR activation by OCA also prevents gut barrier dysfunction and attenuates intestinal inflammation in mouse models of cholestasis and cirrhosis (51, 52) . Therefore, whether intestinal FXR mediates OCA's beneficial effects in NASH remains to be determined.
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